Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
Go back to Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1102.08 +3.51 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1098.57 | 52 Week High | $88.16 | |||
| Open | $1112.24 | 52 Week Low | $67.88 | |||
| Day High | $1119.45 | P/E | 255.11 | |||
| Day Low | $1093.15 | EPS | $4.32 | |||
| Volume | 3,014,837 | |||||
